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Background: Patient satisfaction is the ultimate goal of healthcare system which can be achieved from good
patient-healthcare professional relationship and quality of healthcare services provided.
Study was conducted to determine the baseline satisfaction level of newly diagnosed diabetics and to explore the
impact of pharmaceutical care intervention on patients’ satisfaction during their follow-ups in a tertiary care teaching
hospital in Nepal.
Methods: An interventional, pre-post non-clinical randomised controlled study was designed among randomly
distributed 162 [control group (n = 54), test 1 group (n = 54) and test 2 group (n = 54)] newly diagnosed diabetes
mellitus patients by consecutive sampling method for 18 months. Diabetes Patient Satisfaction Questionnaire was
used to evaluate patient’s satisfaction scores at baseline, three, six, nine and, twelve months’ follow-ups. Test
groups patients were provided pharmaceutical care whereas control group patients only received their usual
care from physician/nurses. The responses were entered in SPSS version 16. Data distribution was not normal on
Kolmogorov-Smirnov test. Non-parametric tests i.e. Friedman test, Mann-Whitney U test and Wilcoxon signed rank
test were used to find the differences among the groups before and after the intervention (p ≤0.05).
Results: There were significant (p < 0.001) improvements in patients’ satisfaction scores in the test groups on
Friedman test. Mann-Whitney U test identified the significant differences in satisfaction scores between test 1
and test 2 groups, control and test 1 groups and, control and test 2 groups at 3-months (p = 0.008), (p < 0.001)
and (p < 0.001), 6-months (p = 0.010), (p < 0.001) and (p < 0.001), 9-months (p < 0.001), (p < 0.001) and (p < 0.001)
and, 12-months (p < 0.001), (p < 0.001) and (p < 0.001) follow-ups respectively.
Conclusion: Pharmaceutical care intervention significantly improved the satisfaction level of diabetics in the test
groups compare to the control group. Diabetic kit demonstration strengthened the satisfaction level among the
test 2 group patients. Therefore, pharmacist can act as a counsellor through pharmaceutical care program and
assist the patients in managing their disease. This will not only modify the patients’ related outcomes and their
level of satisfaction but also improve the healthcare system.
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Patient satisfaction has an important place in the health-
care system. Patient satisfaction can be obtained from a
good patient-healthcare professional relationship, which
influences patient health-related outcomes [1]. The
measurement of patients’ satisfaction is the prominent
method to describe how well the services are provided
with a realistic indication of the quality of healthcare
services, which reflects whether or not the patient has
achieved his/her expectation with the provided services
and also allows assessment of the healthcare professional
performance [2,3]. Patient satisfaction can be viewed as
“the extent of an individual’s experience compared with
his or her expectations” [4] where expectation is “a refer-
ence point consumers use to assess their service experi-
ence” [2]. Patient satisfaction can only be achieved when
patient perception towards healthcare services is opti-
mistic, gratifying and meets their expectation. In Nepal
about 90% of the population lives in rural areas where
healthcare facilities are poor. Moreover, geographical
division of the country isolated the rural areas from cen-
tral areas and has hindered the development of transpor-
tation, communication and health facilities.
Most studies from developed countries have shown
the impact of pharmaceutical care services on patients’
satisfaction [5-8] but studies have not given the attention
in executing any kind of module for better patients’ un-
derstanding about their disease and its management
which is directly linked with patients’ satisfaction. More-
over, studies conducted worldwide to assess the satisfac-
tion level have not targeted the newly diagnosed
diabetes patients whose expectation from healthcare sys-
tem and satisfaction level might be different from those
diabetics receiving the treatment since long time. Studies
addressing the impact of pharmaceutical care services
on patients’ satisfaction level are infancy in developing
countries like Nepal where pharmaceutical care concept
is still in the theoretical stage and pharmacists are still
finding ways to participate in patient care. Therefore, the
present study was conducted to assess the impact of
pharmaceutical care intervention provided by a pharma-
cist on satisfaction level of newly diagnosed diabetes
mellitus patients in Nepal.
Methods
Study design
The study was an interventional, pre-post non-clinical
randomised controlled trial among the control group
(CG), test 1 group (T1G) and test 2 group (T2G) with
three treatment arms exploring the impact of pharma-
ceutical care intervention on satisfaction of newly diag-
nosed diabetes patients at the Manipal Teaching
Hospital, Pokhara, Nepal for a period of 18 months (July
2010 to December 2011). The study was approved bythe Research and Ethics Committee of Manipal Teach-
ing Hospital, Nepal.
Study population
The study population was the newly diagnosed type 1
and type 2 diabetes mellitus patients of aged 16 years
and above. Pregnant women, mentally incompetent pa-
tients and patients not willing to participate in the study
were excluded. Patients who did not come at their first
follow-up were also excluded. Patients were requested to
sign a written consent form as acceptance to participate
in the research study. However, in case of minors, paren-
tal consent was sought and obtained.
Sample size and sampling technique
Sample size was calculated by using a finite population
correction formula [9]. Diabetes prevalence of 9% was
taken as the calculation factor from previous studies
[10,11]. The Z value was set at 1.96, with a 95% of confi-
dence interval and 5% as margin of error. The calculated
sample size was 125 patients. A drop-out margin of 30%
was taken from previous studies [12,13] and added to
the sample to achieve the final targeted sample size of
162 patients. The targeted sample size (162 patients)
was achieved by a consecutive sampling method (based
on time capsule frame) over 6 months duration (from
July 2010 to December 2010) [14]. The randomisation of
162 patients was done by 1:1:1 in three parallel groups
[15]: CG (n = 54), T1G (n = 54) and T2G (n = 54) with-
out disturbing the sequence of randomisation. A total of
ten patients (4 patients from control group and 3 pa-
tients from each test group) did not complete their first
assessment follow-up (3-months) and therefore, further
study was carried out with only 152 patients divided in
to CG (n = 50), T1G (n = 51) and T2G (n = 51).
Study tools
All the study tools and the questionnaire were prepared
in the Nepali language due to language fluency and bar-
riers to the English language among most of the patients
visiting the hospital. Socio-demographic characteristics
of the patients were documented in socio-demography
form. Diabetes information booklet, diabetes complica-
tion chart, diabetic food chart were used as an educa-
tional materials to increase the patients’ awareness about
diabetes and its management. A diabetic kit (including
glass tubings, chart of human anatomy with circulatory
system, daily medication calendar and calendar of antidi-
abetic medicines) was made especially for T2G (PC +
Diabetic kit group) patients to explain about anatomical
and physiological relationship of diabetes and its impact
on physiological system. The purpose to use the diabetic
kit only in T2G patients was to identify whether the
extra demonstration of the kit brings any significant
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Formulation of Diabetes Patient Satisfaction
Questionnaire
The theme and key words of Diabetes Patient Satisfaction
Questionnaire (DPSQ) were extracted and compiled from
different resources [2,3,16-19]. A total of 16 questions
were constructed in English after an in-depth literature re-
view related to patient’s satisfaction/dissatisfaction towards
pharmacist, pharmacy-provided services and treatment
satisfaction following Nepali translation (native language)
of the questionnaire by a professional translator. Eight
questions addressed the patient’s satisfaction/dissatisfac-
tion to pharmacist related parameters like attitude and be-
haviour, professional relationship, concern about the
disease, courtesy and respect, communication ability, con-
tribution/support in diabetes care, ability to answer quer-
ies, and amount of time spent, while the rest 8 questions
focused on information received from the pharmacist
about the disease and medications by using various dia-
betes educational materials. The questionnaire was tested
for its validity before using it in the study.
Validation and scoring method of diabetes patient
satisfaction questionnaire
The face and content validity of the questionnaire was
done by one doctor (diabetologist), three pharmacists
(2 PhDs and 1 master’s degree) and one nurse (master’s
degree). Pilot study was carried out with thirty one
newly diagnosed diabetes patients to test the question-
naire suitability and better patients understanding.
These patients were excluded in the final study. The
Cronbach’s α test for reliability of the questionnaire
was 0.75 and internal consistency level was considered
adequate. The scoring was done on 5-point Likert scale
(very dissatisfied = 1, slightly dissatisfied = 2, neutral = 3,
slightly satisfied = 4 and very satisfied = 5). The neutral
score 48 (3x16 = 48) of patients was taken as the mid-
point to classify the patients’ satisfaction level into
‘least satisfied’ (if median score ≤48) and more satisfied
(if median score >48-80).
Description of pharmaceutical care intervention among
diabetes patients
The pharmaceutical care intervention was categorized
into the intervention phase (phases I to III) and
reinforcement phase (phases IV and V). The control
group patients did not receive pharmaceutical care inter-
vention from pharmacist and maintained on usual care
obtained from physician/nurses throughout the study.
Patients from both the test groups received the infor-
mation about meaning of diabetes, its types, sign and
symptoms, reasons for high blood glucose, risk factors ofdiabetes, different short term (acute) and long term
(chronic) complications of diabetes and role of pharmaco-
logical (antidiabetic medication) and non-pharmacological
(lifestyle modification, diet and exercise) measures in man-
agement of diabetes. Besides this, test groups patients
were also taught about how to administer insulin by using
insulin pen or insulin syringe (if they were prescribed in-
sulin as therapy) and trained regarding the use of gluc-
ometer for self-monitoring of blood glucose (SMBG) at
home. Medication envelopes were used to dispense the
prescribed medication (s) to the patients.
In addition to it, test 2 group patients were demon-
strated about diabetic kit components such as glass tub-
ings showing the change in the viscosity pattern of
blood among diabetic and non-diabetic patients and the
impact of increased sugar on the blood flow in different
organ system with emphasis of blood coagulation and
obstruction in blood flow in blood vessels in diabetes.
Chart of human anatomy with circulator system was de-
scribed to make the patients aware to locate the different
organ system in the body and the supply of blood to
these organs via blood vessels. Special focus was given to
those organs which are mainly affected in diabetes like
cardiac system, renal system, eye and brain. They were
also explained about the location of pancreas and its role
in diabetes. Daily medication calendar and antidiabetic
medicine calendar were used to enhance the patients’
knowledge and compliance about the use of antidiabetic
medication in diabetes management. After completing
the intervention phase, patients were reinforced with the
information in a systematic manner during their
reinforcement phases, as patient education is not one-
time process and it requires continuous reinforcement
by healthcare professionals. All the patients (belonging
to all three groups) were evaluated for their satisfaction
using DPSQ questionnaire before and after disseminat-
ing the pharmaceutical care intervention at baseline and
at three, six, nine and twelve months follow-ups
respectively.
Data collection and statistical analysis
The baseline patients’ satisfaction scores was evaluated
from all three groups and the evaluation was repeated
again at 3-months, 6-months, 9-months and 12-months
using the same questionnaire. The responses were
coded, entered and verified by using Statistical Package
for Social Sciences (SPSS) version 16. Descriptive ana-
lysis such as frequency, mean, standard deviation, me-
dian and inter-quartile range (IQR) was calculated as per
the requirement for data analysis. The scores were found
to be skewed at p < 0.05 significance level when checked
by using the Kolmogorov-Smirnov test. Therefore non-
parametric tests were used as per the applicability to
analyse the patients’ satisfaction scores. Friedman test,
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ences between dependent and independent variables
within and between the groups before and after the in-
terventions respectively. The Wilcoxon signed rank test
was used for pre- and post-comparison within the
groups. Post hoc analysis with Wilcoxon signed rank test
was used to find where the significant differences actu-
ally occurred in the group at new p-value of ≤0.005 after
Bonferroni adjustment. A significance level of ≤0.05 was
used in all analyses.
Results
Socio-demography characteristics of study patients
There were 162 patients enrolled in the study. The
mean age (in years) of the patients was 49.14 ± 12.56.
Males were greater in number (n = 106, 65.43%). The
mean ± sd of the body mass index (BMI) of patients was
27.60 ± 3.54 kg/m2. The median monthly income (in
Nepali rupees, 1USD = 73.38 Nepali rupees) and inter-
quartile range of the patients was 10,000 [(9,000)-
(16,000)]. About 40.7% patients were unemployed,
25.9% businessman, 18.5% employed, 13.6% pensioner
and 1.2% students in the study. The study found 30.9%
patients either primary educated or secondary educated
and, only 24% and 14.2% patients were non-educated
and tertiary educated respectively. There were 92%
patients of non-vegetarian food habits. Nearly 42.6%
and 57.4% patients never had alcohol and smoking
habits respectively while16.7% and 17.9% patients were
found alcoholic and smoking every day. Moreover, only
24.1% and 6.8% patients were occasional and 16.7% and
17.9% were former alcoholic and smoker respectively.
Type 2 diabetics were found more (n = 156, 96.3%) in
the study. Majority of the patients (n = 133, 82.1%) did
not have any family history of diabetes.
Patients’ satisfaction with pharmacist and pharmaceutical
care intervention at baseline and follow-ups
At baseline, patients were ‘neutral’ in response to phar-
macist’s contribution/support (CG: 77.8%, T1G: 87% and
T2G: 50%), pharmacist’s ability to answer the queries
(CG: 72.2%, T1G: 51.9% and T2G: 55.6%) and amount of
time spent by pharmacist (CG: 66.7%, T1G: 63% and
T2G: 79.6%). A perceptible proportion of patients were
not only ‘neutral’ but also ‘slightly dissatisfied’ and ‘very
dissatisfied’ related to pharmaceutical care intervention.
Patients were ‘neutral’ in response to medications used
for diabetes care (CG: 87%, T1G: 66.7% and T2G: 59.3%)
and counselling related to medicine use (CG: 51.9%,
T1G: 55.6% and T2G: 46.3%) while ‘slightly dissatisfied’
to information related to medicine(s) side-effects (CG:
46.3%, T1G: 40.7% and T2G: 42.6%). Furthermore, the
majority of the patients were ‘very dissatisfied’ with vari-
ous diabetes educational material and its effectivenesssuch as the diabetic kit (CG: 50%, T1G: 72.2% and T2G:
83.3%), diabetes complication chart (CG: 64.8%, T1G:
77.8% and T2G: 81.5%), diabetes information booklet
(CG: 94.4%, T1G: 94.4% and T2G: 92.6%), diabetes food
chart (CG: 83.3%, T1G: 75.9% and T2G: 79.6%) and
overall counselling and diabetes education (CG: 72.2%,
T1G: 63% and T2G: 61.1%) in the diabetes awareness
program. Successive educational intervention from
pharmacist using various educational materials related
to diabetes management improved patients’ satisfaction
in subsequent follow-ups. Further details related to
patients’ responses to satisfaction questionnaire are
depicted in Table 1.
Patient satisfaction scores at baseline, 3-months, 6-months,
9-months and 12-months follow-ups
Patients’ responses to satisfaction questionnaire were
analysed using descriptive statistics and responses are
presented as median score and inter-quartile range
(IQR). Patients from the three groups were found ‘least
satisfied’ to pharmacist-provided pharmaceutical care
(median scores <48) at baseline. The test groups patients
perceived a greater improvement in their satisfaction
scores (median scores >48) and found ‘more satisfied’ in
subsequent follow-ups compared to their baseline satis-
faction level due to pharmaceutical care intervention.
The variation in median satisfaction scores between
T1G and T2G was due to the difference in their inter-
ventional approach (use of diabetic kit in T2G). How-
ever, the continuous detrimental in satisfaction scores of
control group patients could be seen during follow-ups
and finally they were found ‘least satisfied’ at twelve
months follow-up (median score <48). Further details
about the satisfaction scores of patients are depicted in
Table 2.
Comparison of patient satisfaction scores at baseline,
3-months, 6-months, 9-months and 12-months follow-ups
within test groups (Test 1 group and Test 2 group)
The statistically significant differences were determined
in patients’ satisfaction scores of the test groups on
Friedman test due to pharmaceutical care intervention
(Table 3).
To find out where the actual differences occurred in
each group on different occasions, post-hoc analysis with
the Wilcoxon signed rank test was used. The differences
in satisfaction scores were considered significant at
p ≤ 0.005 level (2-tailed) after Bonferroni adjustment. In
test 1 group, the statistically significant differences in pa-
tients’ satisfaction scores were noted between baseline
and first follow-up (Z = -6.221, p < 0.001), baseline and
second follow-up (Z = -6.227, p < 0.001), baseline and
third follow-up (Z = -6.219, p < 0.001), baseline and
fourth follow-up (Z = -6.210, p < 0.001) and, first and
Table 1 Patients’ satisfaction with pharmacist and pharmaceutical care intervention at baseline and follow-ups
Items Groups Control group n (%) Test 1 group (PC group) n (%) Test 2 group (PC + Diabetes kit group) n (%)
Scales Baseline 3 month 6 month 9 month 12 month Baseline 3 month 6 month 9 month 12 month Baseline 3 month 6 month 9 month 12 month
Pharmacist attitude
and behaviour
VD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0 0 0 0 0 1 (1.9) 0 0 0
N 8 (14.8) 0 11 (22) 8 (16) 6 (12) 5 (9.3) 0 0 0 0 3 (5.6) 0 0 0 0
SS 37 (68.5) 36 (72) 31 (62) 31 (62) 34 (68) 38 (70.4) 8 (15.7) 7 (13.7) 5 (9.8) 13 (25.5) 40 (74.1) 9 (17.6) 8(15.7) 9 (17.6) 8 (15.7)
VS 9 (16.7) 14 (28) 8 (16) 11 (22) 10 (20) 11 (20.4) 43 (84.3) 44 (86.2) 46 (90.2) 38 (74.5) 11 (20.4) 41 (80.4) 43 (84.3) 42 (82.3) 43 (84.3)
Pharmacist’s
professional
relationship
VD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0 0 0 0 0 1 (1.9) 0 0 0
N 8 (14.8) 33 (66) 39 (78) 41 (82) 41 (82) 17 (31.5) 15 (29.4) 18 (35.3) 16 (31.4) 7 (13.7) 14 (25.9) 22 (43.1) 24 (47.0) 21 (41.1) 8 (15.7)
SS 31 (57.4) 17 (34) 11 (22) 7 (14) 9 (18) 28 (51.9) 23 (45.1) 20 (39.2) 25 (49) 34 (66.7) 30 (55.6) 23 (45.1) 25 (49) 25 (49) 38 (74.5)
VS 15 (27.8) 0 0 2 (4) 0 9 (16.7) 13 (25.5) 13 (25.5) 10 (19.6) 10 (19.6) 10 (18.5) 5 (9.8) 2 (3.9) 5 (9.8) 5 (9.8)
Pharmacist’s concern
about patients’
disease
VD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
N 24 (44.4) 11 (22) 15 (30) 10 (20) 14 (28) 15 (27.8) 4 (7.8) 4 (7.8) 2 (3.9) 0 11 (20.4) 1 (1.9) 2 (3.9) 0 1 (1.9)
SS 25 (46.3) 38 (76) 35 (70) 39 (78) 36 (72) 36 (66.7) 27 (52.9) 25 (49) 29 (56.9) 28 (54.9) 37 (68.5) 40 (78.4) 40 (78.4) 37 (72.5) 19 (37.2)
VS 5 (9.3) 1 (2) 0 1 (2) 0 3 (5.6) 20 (39.2) 22 (43.1) 20 (39.2) 23 (45.1) 6 (11.1) 10 (19.6) 9 (17.6) 14 (27.4) 31 (60.8)
Pharmacist’s courtesy
and respect
VD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
N 0 3 (6) 6 (12) 7 (14) 7 (14) 3 (5.6) 0 0 0 0 1 (1.8) 0 0 0 0
SS 22 (40.7) 38 (76) 35 (70) 39 (78) 36 (72) 25 (46.3) 19 (37.2) 23 (45.1) 8 (15.7) 4 (7.8) 19 (35.2) 13 (25.5) 15 (29.4) 8 (15.7) 4 (7.8)
VS 32 (59.3) 9 (18) 9 (18) 4 (8) 7 (14) 26 (48.1) 32 (62.7) 28 (54.9) 43 (84.3) 47 (92.1) 34 (63.0) 38 (74.5) 36 (70.6) 43 (84.3) 47 (92.1)
Pharmacist’s
communication
ability
VD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
N 6 (11.1) 4 (8) 4 (8) 7 (14) 6 (12) 2 (3.7) 0 0 1 (1.9) 0 3 (5.6) 1 (1.9) 0 0 0
SS 43 (79.6) 44 (88) 46 (92) 43 (86) 34 (68) 41 (75.9) 33 (64.7) 35 (68.6) 28 (54.9) 30 (58.8) 48 (88.9) 39 (76.5) 43 (84.3) 40 (78.4) 34 (66.7)
VS 5 (9.3) 2 (4) 0 0 0 11 (20.4) 18 (35.3) 16 (31.4) 22 (43.1) 21 (41.2) 3 (5.6) 11 (21.6) 8 (15.7) 11 (21.6) 17 (33.3)
Pharmacist’s
contribution/support
VD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SD 6 (11.1) 0 0 0 0 2 (3.7) 0 0 0 0 19 (35.2) 0 0 0 0
N 42 (77.8) 15 (30) 22 (44) 28 (56) 32 (64) 47 (87.0) 5 (9.8) 2 (3.9) 4 (7.8) 3 (5.9) 27 (50) 2 (3.9) 2 (3.9) 1 (1.9) 0
SS 6 (11.1) 35 (70) 27 (54) 22 (44) 18 (36) 5 (9.3) 30 (58.8) 34 (66.7) 31 (60.8) 32 (62.7) 8 (14.8) 42 (82.3) 40 (78.4) 40 (78.4) 30 (58.8)
VS 0 0 1 (2) 0 0 0 16 (31.4) 15 (29.4) 16 (31.4) 16 (31.4) 0 7 (13.7) 9 (17.6) 10 (19.6) 21 (41.2)
Pharmacist’s ability to
answer the queries
VD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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Table 1 Patients’ satisfaction with pharmacist and pharmaceutical care intervention at baseline and follow-ups (Continued)
N 39 (72.2) 19 (38) 9 (18) 16 (32) 12 (24) 28 (51.9) 3 (5.9) 1 (1.9) 0 0 30 (55.6) 2 (3.9) 1 (1.9) 0 0
SS 15 (27.8) 31 (62) 41 (82) 34 (68) 36 (72) 26 (48.1) 29 (56.8) 31 (60.8) 30 (58.8) 27 (52.9) 24 (44.4) 36 (70.6) 37 (72.5) 36 (70.6) 29 (56.8)
VS 0 0 0 0 2 (4) 0 19 (37.2) 19 (37.2) 21 (41.1) 24 (47.0) 0 13 (25.5) 13 (25.5) 15 (29.4) 22 (43.1)
Amount of time
spent by pharmacist
VD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SD 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
N 36 (66.7) 22 (44) 8 (16) 9 (18) 10 (20) 34 (63.0) 1 (1.9) 0 0 0 43 (79.6) 1 (1.9) 2 (3.9) 0 0
SS 18 (33.3) 28 (56) 40 (80) 37 (74) 33 (66) 20 (37.0) 25 (49) 21 (41.1) 20 (39.2) 16 (31.4) 11 (20.4) 34 (66.7) 35 (68.6) 33 (64.7) 19 (37.2)
VS 0 0 2 (4) 4 (8) 7 (14) 0 25 (49) 30 (58.8) 31 (60.8) 35 (68.6) 0 16 (31.4) 14 (27.4) 18 (35.3) 32 (62.7)
Effectiveness of
diabetic kit in
diabetes awareness
VD 27 (50) 36 (72) 35 (70) 35 (70) 37 (74) 39 (72.2) 30 (58.8) 28 (54.9) 26 (51) 25 (49)) 45 (83.3) 0 0 0 0
SD 18 (33.3) 14 (28) 11 (22) 10 (20) 11 (22) 8 (14.8) 15 (29.4) 13 (25.5) 12 (23.5) 10 (19.6) 5 (9.3) 0 0 0 0
N 9 (16.7) 0 4 (8) 5 (10) 2 (4) 7 (13.0) 6 (11.8) 10 (19.6) 13 (25.5) 16 (31.4) 4 (7.4) 0 0 0 0
SS 0 0 0 0 0 0 0 0 0 0 0 21 (41.2) 20 (39.2) 15 (29.4) 11 (21.6)
VS 0 0 0 0 0 0 0 0 0 0 0 30 (58.8) 31 (60.8) 36 (70.6) 40 (78.4)
Effectiveness of
diabetes
complication chart
VD 35 (64.8) 30 (60) 24 (48) 19 (38) 27 (54) 42 (77.8) 0 0 0 0 44 (81.5) 0 0 0 0
SD 14 (25.9) 17 (34) 13 (26) 20 (40) 18 (36) 6 (11.1) 0 0 0 0 6 (11.1) 0 0 0 0
N 5 (9.3) 3 (6) 13 (26) 11 (22) 5 (10) 6 (11.1) 0 0 0 0 4 (7.4) 0 0 0 0
SS 0 0 0 0 0 0 20 (39.2) 16 (31.4) 15 (29.4) 12 (23.5) 0 18 (35.3) 9 (17.6) 12 (23.5) 4 (7.8)
VS 0 0 0 0 0 0 31 (60.8) 35 (68.6) 36 (70.6) 39 (76.4) 0 33 (64.7) 42 (82.4) 39 (76.5) 47 (92.2)
Effectiveness of
diabetes information
booklet
VD 51 (94.4) 27 (54) 22 (44) 20 (40) 28 (56) 51 (94.4) 0 0 0 0 50 (92.6) 0 0 0 0
SD 3 (5.6) 9 (18) 15 (30) 13 (26) 18 (36) 2 (3.7) 0 0 0 0 3 (5.6) 0 0 0 0
N 0 13 (26) 13 (26) 17 (34) 4 (8) 1 (1.8) 1 (1.9) 1 (1.9) 1 (1.9) 1 (1.9) 1 (1.8) 1 (1.9) 0 0 0
SS 0 1 (2) 0 0 0 0 28 (54.9) 24 (47.1) 26 (51) 24 (47.1) 0 18 (35.3) 16 (31.4) 22 (43.1) 17 (33.3)
VS 0 0 0 0 0 0 22 (43.1) 26 (51) 24 (47.1) 26 (51) 0 32 (62.7) 35 (68.6) 29 (56.9) 34 (66.7)
Effectiveness of
diabetic food chart
VD 45 (83.3) 3 (6) 3 (6) 2 (4) 3 (6) 41 (75.9) 0 0 0 0 43 (79.6) 0 0 0 0
SD 3 (5.6) 5 (10) 4 (8) 6 (12) 9 (18) 7 (13) 0 0 0 0 0 0 0 0 0
N 4 (7.4) 15 (30) 26 (52) 26 (52) 27 (54) 6 (11.1) 0 0 0 0 7 (13) 0 0 0 0
SS 2 (3.7) 27 (54) 17 (34) 16 (32) 11 (22) 0 2 (3.9) 3 (5.9) 1 (1.9) 1 (1.9) 4 (7.4) 3 (5.9) 3 (5.9) 5 (9.8) 1 (1.9)
VS 0 0 0 0 0 0 49 (96.1) 48 (94.1) 50 (98) 50 (98) 0 48 (94.1) 48 (94.1) 46 (90.2) 50 (98)
Effectiveness of
overall counselling
and education
programme
VD 39 (72.2) 29 (58) 28 (56) 30 (60) 24 (48) 34 (63.0) 0 0 0 0 33 (61.1) 0 0 0 0
SD 14 (25.9) 16 (32) 19 (38) 15 (30) 22 (44) 14 (25.9) 0 0 0 0 13 (24.1) 0 0 0 0
N 1 (1.8) 5 (10) 3 (6) 5 (10) 4 (8) 6 (11.1) 6 (11.8) 3 (5.9) 4 (7.8) 3 (5.9) 8 (14.8) 7 (13.7) 8 (15.7) 5 (9.8) 3 (5.9)
SS 0 0 0 0 0 0 29 (56.8) 32 (62.7) 37 (72.5) 36 (70.6) 0 33 (64.7) 33 (64.7) 35 (68.6) 31 (60.8)
VS 0 0 0 0 0 0 16 (31.4) 16 (31.4) 10 (19.6) 12 (23.5) 0 11 (21.6) 10 (19.6) 11 (21.6) 17 (33.3)
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Table 1 Patients’ satisfaction with pharmacist and pharmaceutical care intervention at baseline and follow-ups (Continued)
Medication used for
diabetes treatment
VD 2 (3.7) 0 0 0 0 11 (20.4) 0 0 0 0 10 (18.5) 0 0 0 0
SD 5 (9.3) 0 0 4 (8) 6 (12) 7 (13.0) 0 0 0 0 8 (14.8) 0 0 0 0
N 47 (87.0) 11 (22) 22 (44) 23 (46) 30 (60) 36 (66.7) 20 (39.2) 14 (27.4) 12 (23.5) 10 (19.6) 32 (59.3) 21 (41.2) 18 (35.3) 9 (17.6) 6 (11.8)
SS 0 38 (76) 26 (52) 23 (46) 14 (28) 0 3 (5.9) 4 (7.8) 3 (5.9) 3 (5.9) 4 (7.4) 14 (27.4) 8 (15.7) 4 (7.8) 1 (1.9)
VS 0 1 (2) 2 (4) 0 0 0 28 (54.9) 33 (64.7) 36 (70.6) 38 (74.5) 0 16 (31.4) 25 (49) 38 (74.5) 44 (86.2)
Counselling related
to medicines use
VD 8 (14.8) 0 0 0 0 7 (13.0) 0 0 0 0 13 (24.1) 0 0 0 0
SD 17 (31.5) 0 6 (12) 10 (20) 1 (2) 11 (20.4) 0 0 0 0 11 (20.4) 0 0 0 0
N 28 (51.9) 15 (30) 19 (38) 12 (24) 13 (26) 30 (55.6) 20 (39.2) 14 (27.4) 12 (23.5) 10 (19.6) 25 (46.3) 21 (41.2) 18 (35.3) 9 (17.6) 6 (11.8)
SS 1 (1.8) 33 (66) 21 (42) 23 (46) 35 (70) 6 (11.1) 4 (7.8) 2 (3.9) 3 (5.9) 1 (1.9) 5 (9.3) 6 (11.8) 7 (13.7) 5 (9.8) 1 (1.9)
VS 0 2 (4) 4 (8) 5 (10) 1 (2) 0 27 (52.9) 35 (68.6) 36 (70.6) 40 (78.4) 0 24 (47) 26 (50.9) 37 (72.5) 44 (86.2)
Information about
side effects of
medicines
VD 8 (14.8) 6 (12) 8 (16) 6 (12) 0 10 (18.5) 0 0 0 0 17 (31.5) 1 (1.9) 0 0 0
SD 25 (46.3) 24 (48) 29 (58) 28 (56) 25 (50) 22 (40.7) 2 (3.9) 2 (3.9) 3 (5.9) 0 23 (42.6) 5 (9.8) 2 (3.9) 2 (3.9) 2 (3.9)
N 21 (38.9) 20 (40) 12 (24) 16 (32) 25 (50) 18 (33.3) 32 (62.7) 19 (37.2) 18 (35.3) 15 (29.4) 9 (16.7) 19 (37.2) 17 (33.3) 18 (35.3) 15 (29.4)
SS 0 0 1 (2) 0 0 4 (7.4) 17 (33.3) 29 (56.8) 30 (58.8) 35 (68.6) 5 (9.3) 26 (50.9) 32 (62.7) 31 (60.8) 32 (62.7)
VS 0 0 0 0 0 0 0 1 (1.9) 0 1 (1.9) 0 0 0 0 2 (3.9)
VD = very dissatisfied, SD = slightly dissatisfied, N = neutral, SS = slightly satisfied, VS = very satisfied.
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Table 2 Patients’ satisfaction scores at baseline, 3-months, 6-months, 9-months and 12-months follow-ups
Groups Control group Test 1 group (PC group) Test 2 group (PC + Diabetic kit group)
Follow-ups Median score (IQR) Median score (IQR) Median score (IQR)
Baseline 44 [(42)-(46)] 45 [(42)-(46)] 43 [(41)-(46)]
3-months (1st F/U) 50 [(48)-(51)] 66 [(64)-(69)] 68 [(66)-(70)]
6-months (2nd F/U) 49 [(48)-(50)] 67 [(65)-(70)] 69 [(66)-(71)]
9-months (3rd F/U) 49 [(48)-(50)] 68 [(66)-(70)] 69 [(68)-(73)]
12-months (4th F/U) 47.74 [(47)-(48.25)] 68 [(66)-(70)] 73 [(70)-(75)]
Upadhyay et al. BMC Health Services Research  (2015) 15:57 Page 8 of 10fourth follow-up (Z = -3.072, p = 0.002). On the other
hand, in test 2 group, the significant differences were found
between baseline and first follow-up (Z = -6.222, p < 0.001),
baseline and second follow-up (Z = -6.331, p < 0.001),
baseline and third follow-up (Z = -6.228, p < 0.001),
baseline and fourth follow-up (Z = -6.117, p < 0.001), first
and third follow-up (Z = -3.047, p = 0.002), first and
fourth follow-up (Z = -5.522, p < 0.001), second and
fourth follow-up (Z = -5.658, p < 0.001) and, third and
fourth follow-up (Z = -4.487, p < 0.001).Comparison of patients’ satisfaction scores between test
groups and, control group and test groups
Mann-Whitney U test was used to analyse the differ-
ences in satisfaction scores of patients between test
groups and, control group and test groups. The test re-
vealed the statistical significant differences in satisfaction
scores of patients at three, six, nine and twelve months
follow-ups between the groups. Further details about dif-
ferences in satisfaction scores between the test groups
and, control and test groups are mentioned in Table 4.Discussion
Consumer satisfaction is linked with the quality of ser-
vices provided to them, which indicates whether the ser-
vices fulfilled the consumers’ expectations or not. In the
context of healthcare services, the patients’ expectation
is to receive good quality care and to achieve better
health-related outcomes. Being an important member ofTable 3 Comparison of patients’ satisfaction scores at baseline
within test groups (Test 1 group and Test 2 group)
Groups Test 1 group (PC group
Follow-ups Median score (IQR)
Baseline 45 [(42)-(46)]
3-months (1st F/U) 66 [(64)-(69)]
6-months (2nd F/U) 67 [(65)-(70)]
9-months (3rd F/U) 68 [(66)-(70)]
12-months (4th F/U) 68 [(66)-(70)]
p-value* <0.001**
*Friedman test.
**Differences were significant at ≤0.05 level (2-tailed).healthcare team, it is the prime responsibility of the
pharmacist to provide good services to patients.
At baseline, patients from the three groups were found
‘slightly satisfied’ with the components indicating the
pharmacist’s attitude and behaviour, professional rela-
tionship, concern and communication ability, and ‘very
satisfied’ with courtesy and respect received from the
pharmacist. However, patients were ‘neutral’ with regard
to pharmacist contribution/support, ability to answer the
queries, and time spent. Patients were found to be
‘slightly satisfied’ and ‘very satisfied’ with few compo-
nents related to pharmacist at baseline this could be the
result of informal introductory session (to make the fur-
ther conversation more friendly) between pharmacist
and patients at their first meeting before proceeding to
patient evaluation. Patients were ‘very dissatisfied’ with
the use of various educational materials like diabetic kit,
complication chart, diabetes information booklet, dia-
betic food chart and overall counselling and education
program. They were ‘neutral’ with regard to diabetes
medication and medication counselling while ‘slightly
dissatisfied’ with the information related to medicine
side-effects [20]. There were no significant differences in
satisfaction scores of patients among the three groups
and they were ‘least satisfied’ at baseline to pharmaceut-
ical services.
Because of increasing patient burden, physicians are
hardly getting enough time to listen patients’ problems
with compassion and explaining about their disease and
medication use to them. This could also be one of the, 3-months, 6-months, 9-months and 12-months follow-ups
) Test 2 group (PC + Diabetic kit group)
Median score (IQR)
43 [(41)-(46)]
68 [(66)-(70)]
69 [(66)-(71)]
69 [(68)-(73)]
73 [(70)-(75)]
<0.001**
Table 4 Comparison of patients’ satisfaction scores between test groups (Test 1 group and Test 2 group) and, control
group and test groups
Median satisfaction scores (IQR)
Follow-ups Baseline 3-months (1stFollow-up) 6-months (2ndFollow-up) 9-months (3rdFollow-up) 12-months (4thFollow-up)
Groups T1G 45 (42)-(46) 66 (64)-(69) 67 (65)-(70) 68 (66)-(70) 68 (66)-(70)
T2G 43 (41)-(46) 68 (66)-(70) 69 (66)-(71) 69 (68)-(73) 73 (70)-(75)
CG 44 (42)-(46) 50 (48)-(51) 49 (48)-(50) 49 (48)-(50) 47.74 (47)-(48.25)
p-value* T1G / T2G 0.096 0.008** 0.010** <0.001** <0.001**
CG / T1G 0.618 <0.001** <0.001** <0.001** <0.001**
CG / T2G 0.179 <0.001** <0.001** <0.001** <0.001**
*Mann-Whitney U test.
**Differences were significant at ≤0.05 level (2-tailed).
Upadhyay et al. BMC Health Services Research  (2015) 15:57 Page 9 of 10reasons for patients’ dissatisfaction, which is supported
by a study where authors identified patients’ dissatisfac-
tion with respect to their willingness to listen with sym-
pathy and explaining their problems in the out-patient
clinic [20]. Another study from Saudi Arabia also de-
scribed the need of more attention with the patients re-
ceiving antidiabetic medication in order to improve their
treatment satisfaction [21]. Therefore, being an import-
ant member of healthcare team and easily accessible to
patients, pharmacist can assist the physicians in order to
enhance patients’ awareness about their disease and
proper use of medication in disease management. This
combined effort of healthcare professionals may increase
the patient satisfaction which was found more with pa-
tients of test groups than control group in present study.
In general, patient satisfaction improved significantly
in all aspects related to the pharmacist and diabetes edu-
cation. Most of the patients were found ‘very satisfied’
with the pharmacist’s courtesy and respect and, attitude
and behaviour [16] at twelve months but a considerable
number of patients were ‘slightly satisfied’ with the phar-
macists’ professional relationship. For other components
related to the pharmacist, patient satisfaction ranged be-
tween ‘slightly satisfied’ to ‘very satisfied’. Furthermore,
most of the patients were ‘very satisfied’ with the use of
the diabetic food chart, diabetes complication chart,
medication counselling and diabetic medications [22]
while a perceptible number of patients were ‘slightly sat-
isfied’ with the information related to medication side-
effects. Similarly, patients achieved their goal of diabetic
nutrition and medicines through diabetes educational
program and hence improved patient satisfaction [19].
Patient satisfaction related to other components of dia-
betes education and counselling ranged between ‘slightly
satisfied’ to ‘very satisfied’. The median satisfaction scores
of the test groups were significantly greater than their
baseline median satisfaction scores. Mann-Whitney U test
identified the significant differences in satisfaction scores
between the test groups due to differences in their inter-
ventional approach throughout the study period.Comparing the present findings from previous studies
related to patients’ satisfaction, one study from Brazil de-
scribed the overall patient satisfaction with regard to
pharmacy and pharmaco-therapeutic services [8]. More-
over, another study also explained the impact of pharma-
cist provided education on diabetes, lifestyle modification
and pharmaco-therapeutic counselling which improved
patients’ clinical and quality of life outcomes and, hence
patients’ satisfaction [7]. In a community-based study
where pharmacist-provided disease-related education
using disease information leaflets and medication counsel-
ling upgraded the satisfaction level of hypertensive pa-
tients [17]. Importance of the pharmaceutical care
program was also indicated from one randomised con-
trolled trial where authors revealed the improvements in
patient satisfaction with regard to clinical pharmacist-
provided care and provision of medication information
[6]. Strengthening the present finding with one Canadian
study highlighted patient satisfaction with courtesy of the
pharmacist, written information about the detailed care
plan for the disease, medication use and its side effects at
community pharmacies [23].
Although, there were slight improvements in satisfac-
tion scores of the control group patients initially due to
doctor- and nurse-provided care but a decreasing trend
in satisfaction scores of the patients could be noticed in
subsequent follow-ups. The consistent decreasing trends
in satisfaction scores of control group patients in each
follow-up indicates that the patients did not achieve
their desired expectation and they were still facing prob-
lems in coping the disease.
Conclusion
Pharmaceutical care intervention significantly improved
the patients’ satisfaction in both the test groups com-
pared to the control group throughout the study.
Pharmacist involvement in patient care through pharma-
ceutical care services increased the level of patient’s sat-
isfaction with all the aspects related to pharmacist and
provided care. Intervention was more pronounced in
Upadhyay et al. BMC Health Services Research  (2015) 15:57 Page 10 of 10improving patients’ satisfaction with regard to pharma-
cist’s courtesy and respect, attitude and behaviour, use of
diabetic food chart, complication chart, medication
counselling and medication used for diabetes care. It
was noticed that the improvements were more promin-
ent among test 2 group patients because of the demon-
stration of the diabetic kit. Therefore, the present
finding indicates that the pharmacists can act as a
counsellor through pharmaceutical care program that
will not only improve the healthcare system but also
modify the patients’ related outcomes and hence in-
crease the satisfaction level of patients by helping them
in managing their disease.Limitations of the study
The present study also had a few limitations. Diabetes
patients were selected from only one hospital of the
Kaski district in western Nepal and hence the study find-
ings may not be able to generalize to the entire diabetes
population of the country. A repeat measurement bias
was expected since the same self-administered question-
naire was given to the participants. To limit this bias,
however, patients were asked to complete the question-
naires in the presence of researcher.
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